metabolic research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
absorption 1. The physical or chemical process by which a substance in one state becomes incorporated into and retained by another substance of a different state. Absorption differs from adsorption in that the first substance permeates the entire bulk of the second substance, rather than just adhering to the surface. 2. The process by which matter (typically electrons bound in atoms) takes up the energy of electromagnetic radiation and transforms it into any of various types of internal energy, such as thermal energy. This type of absorption is the principle on which spectrophotometry is based.
Lately First UK Offshore Wind Champion and Chair, Offshore Wind Acceleration Taskforce. For services to Offshore Wind Energy. Ruth Beatrice Pitter. Member, Anchor Society and Member, Stand Against Racism and Inequality. For services to Equality, to Charity and to the community in Bristol. Andrew Geoffrey Pollock. Founder, CLEVR Money. For services to Financial Inclusion. Phillip George Potter. Regional Lead, West Midlands, Wales and South West, UK Export Finance. For services to Business and to the community in Worcestershire. Jeffrey Richard Powell. Sports Writer and Columnist, Daily Mail. For services to Journalism and to Sport. Patricia Mary Pritchard. For services to Childcare and Early Years. Dr. Heidi Probst. Researcher, Lecturer and lately Director, Health Research Institute, Sheffield Hallam University. For services to Radiography. Howard John Provis. For services to the Welsh Blood Transfusion Service and to the community in Barry and the Vale of Glamorgan. Brian Thomas James Purcell. Lately Northern District Manager, St John Ambulance. For voluntary service in Northern Ireland. Anthony Martin Quinn. Lately Business Development Director, Co-operation Ireland. For services to Community Relations in Northern Ireland. Jayshree Rajkotia. Trustee and Vice Chair, Bharatiya Vidhya Bhavan, Institute of Indian Art and Culture. For services to Indian Culture. Melinda Elizabeth Raker, DL. Founder and Patron, The YANA Charity. For services to Rural Mental Health and Wellbeing. Laura-Jane Rawlings. Chief Executive Officer, Youth Employment UK. For services to Young People.
In physics and chemistry, binding energy is the smallest amount of energy required to remove a particle from a system of particles or to disassemble a system of particles into individual parts. In the former meaning the term is predominantly used in condensed matter physics, atomic physics, and chemistry, whereas in nuclear physics the term separation energy is used. A bound system is typically at a lower energy level than its unbound constituents. According to relativity theory, a ΔE decrease in the total energy of a system is accompanied by a decrease Δm in the total mass, where Δmc2 = ΔE.
This was also the belief of geologist Palmer, who convinced Steven Jones that the helium-3 occurring naturally in Earth perhaps came from fusion involving hydrogen isotopes inside catalysts like nickel and palladium. This led their team in 1986 to independently make the same experimental setup as Fleischmann and Pons (a palladium cathode submerged in heavy water, absorbing deuterium via electrolysis). Fleischmann and Pons had much the same belief, but they calculated the pressure to be of 1027 atmospheres, when cold fusion experiments achieve a loading ratio of only one to one, which has only between 10,000 and 20,000 atmospheres. John R. Huizenga says they had misinterpreted the Nernst equation, leading them to believe that there was enough pressure to bring deuterons so close to each other that there would be spontaneous fusions.
=== Mechanical properties === Crystalline cellulose has a stiffness about 140–220 GPa, comparable with that of Kevlar and better than that of glass fiber, both of which are used commercially to reinforce plastics. Films made from nanocellulose have high strength (over 200 MPa), high stiffness (around 20 GPa) but lack of high strain (12%). Its strength/weight ratio is 8 times that of stainless steel. Fibers made from nanocellulose have high strength (up to 1.57 GPa) and stiffness (up to 86 GPa).
Sources: en.wikipedia.org
Often-discussed contributing factors include feelings, emotions, life satisfaction, achievement, finding a sense of meaning, interpersonal relationships, and health. Well-being is relevant to many fields of inquiry. Positive psychology studies the factors and conditions of optimal human functioning. Philosophy examines the nature and theoretical foundations of well-being and its role as a goal of human conduct. Other related disciplines include economics, sociology, anthropology, medicine, education, politics, and religion. Although the philosophical study of well-being dates back millennia, research in the empirical sciences has intensified only since the second half of the 20th century.
The end of the Hundred Years War in 1453 meant that Britain, and thus Bristol, lost its access to Gascon wines and so imports of Spanish and Portuguese wines increased. Imports from Ireland included fish, hides and cloth (probably linen). Exports to Ireland included broadcloth, foodstuffs, clothing and metals. It has been suggested that the decline of Bristol's Iceland trade for 'stockfish' (freeze dried cod) was a hard blow to the local economy, encouraging Bristol merchants to turn west, launching unsuccessful voyages of exploration in the Atlantic by 1480 in search of the phantom island of Hy-Brazil. More recent research, however, has shown that the Iceland trade was never more than a minor part of Bristol's overseas trade and that the English fisheries off Iceland actually increased during the late 15th and 16th centuries. In 1487, when king Henry VII visited the city, the inhabitants complained about their economic decline. Such complaints, however, were not uncommon among corporations that wished to avoid paying taxes, or which hoped to secure concessions from the Crown. In reality, Bristol's customs accounts show that the port's trade was growing strongly during the last two decades of the fifteenth century. In great part this was due to the increase of trade with Spain.
On June 3, 1942, which was during World War II, in what were the only two invasions of the United States during the war, small parts of the Aleutian islands were occupied by Japanese forces, when Attu and Kiska were invaded possibly to divert American forces away from the main Japanese attack at Midway Atoll. The U.S. Navy, having broken the Japanese naval codes, proceeded as if this was just a diversion, and it did not expend large amounts of effort in defending the islands. More than 90 Americans were taken to Japan as prisoners of war. The United States moved most of the remaining civilian population (over 800) of the Aleutians and Pribilovians to camps in the Alaska Panhandle. In May 1943, American forces invaded Japanese-held Attu and defeated the Japanese. In August 1943, American and Canadian troops launched an invasion of Kiska, in which 34,426 men composed of both Americans and Canadian participated; however, Japanese forces had already evacuated the island, ending the campaign in the islands. The invasion was an embarrassment for the Allied forces as the entire Japanese force of 5,183 men had left the island on July 28 without the Americans noticing; however, the Americans suffered significant casualties during their "invasion"—313 men died as a result of accidents, with many dying due to accidental fire. President Roosevelt visited Adak in 1944, meeting with commanders and eating with soldiers of the garrison. This was his first and only trip to the Aleutian Islands and Alaska as a whole.
=== Education === Platt attended a progressive boarding school named Colorado Rocky Mountain School in Carbondale, Colorado. Platt majored in drama at Tufts University, where he met and became close friends with Hank Azaria. He spent three years working in theatre in Boston, Massachusetts, which he said had a "wealth of serious amateur theatre at that time…I played many roles, and it was the best training I could have had." Platt travelled with Shakespeare and Company, based in Lenox, Massachusetts, touring schools to earn his Equity card, before moving to New York. Platt's early career involved Off-Broadway and regional theatre, and he appeared onstage with the New York Shakespeare Festival, Lincoln Center Theater, Manhattan Theatre Club and other companies across many genres. He obtained an agent while working at Manhattan Punch Line Theatre, and met actor Bill Murray at his cousin's Christmas party. Murray attended Platt's show and recommended Platt to director Jonathan Demme, who cast him in Married to the Mob in 1988. Platt attributes his breakthrough to appearing at the Punch Line Theater.
=== Personal objections === Sometimes people refuse blood transfusions because of fears about the safety of the blood supply. Generally speaking, the rules of informed consent allow mentally competent adults to refuse blood transfusions even when their objections are based on misinformation or prejudice and even when their refusal may result in serious and permanent harm, including death. For example, since COVID-19 vaccines became available, some people have refused blood transfusions because the donor might have been vaccinated, and they fear that this would cause secondhand harm to them. This choice is based on false beliefs, but a mentally competent adult's choices are normally respected. However, if doctor's opinions are that parents and guardians are making harmful choices about children, they can be overruled (in some jurisdictions) using legal arguments based on the harm principle; in this case if doctors believe that refusing the blood transfusion would put the child at risk of serious injury or death. Blood banks do not collect information that is irrelevant to the transfusion process, including the donors' race, ethnicity, sexual orientation, COVID-19 vaccination status, etc., so selecting blood units based on the individual's personal objections is not practical.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.